A prospective, multicenter, randomized, comparator-controlled, evaluator-blinded study to evaluate the safety and effectiveness of VP1 Lido US for volume augmentation of the cheek
- Conditions
- Cheek Volume Augmentation
- Registration Number
- DRKS00033802
- Lead Sponsor
- Merz North America, Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 202
Has a symmetrical rating of 2 (moderate) or 3 (severe) for right and left cheek on the Merz Cheeks Fullness Assessment Scale (MCFAS)
- Desires cheek augmentation to correct volume deficit in the midface and is willing to receive sufficient volume to achieve at least a 1-point improvement on the MCFAS
- Skin or fat atrophy in the midfacial region other than that related to age.
- Subjects with body mass index of <18.5 or =30
- Acute inflammatory process or active infection at the injection site (e.g., acne, eczema, streptococcus infections), or history of chronic or recurrent infection or inflammation with the potential to interfere with the study results or increase the risk of AEs.
- Prior surgery, including midfacial plastic surgery, or has a permanent implant or graft in the midfacial region that could interfere with effectiveness assessments.
- Received midfacial region treatments with porcine-based collagen fillers or with RADIESSE® or with volumizing hyaluronic acid fillers such as but not limited to Juvéderm® Voluma, Restylane® Lyft within the past 24 months and/or with other HA fillers or mesotherapy within the past 12 months or plans to receive such treatments during participation in the study.
- Received facial dermal therapies (i.e., facial ablative or fractional laser, dermabrasion, chemical peels, non-invasive skin-tightening [e.g., Ultherapy®, Thermage®] and surgical procedures) in the midfacial region within the past 12 months or plans to receive them in the facial region during participation in the study.
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Change From Baseline to Week 12 on the Merz Cheeks Fullness Assessment Scale (MCFAS) as Assessed by a Blinded Evaluator
- Secondary Outcome Measures
Name Time Method - Change From Baseline to Week 12 on the MCFAS as Assessed by a Blinded Evaluator by Injection Type (Cannula, Needle)<br>- Treatment Response Rate Where Response is Defined as a = 1-point Improvement on Both Cheeks When Comparing the Change From Baseline to Week 12<br>- FACE-Q Satisfaction With Cheeks for Treated Subjects at Baseline and Week 12<br>- Global Aesthetic Improvement Scale (GAIS) Scores for Treated Subjects at Week 12, as Completed by the Treating Investigator<br>- GAIS Scores for Treated Subjects at Week 12, as Completed by the Subject<br>- Responder Rates at Week 12, According to the MCFAS, as Assessed by Three Blinded Board-certified Independent Panel Reviewers (IPRs) Using Subject Photographs<br>- Incidence of Related Serious or Delayed Onset Adverse Events (>21 Days After Treatment) Following the First Treatment Including Touch-up Until Week 48